Western Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$728K Buy
1,631
+1,003
+160% +$468K 0.03% 541
2025
Q4
$285K Buy
628
+52
+9% +$22.4K 0.01% 679
2025
Q3
$226K Sell
576
-45
-7% -$18.8K 0.01% 697
2025
Q2
$276K Sell
621
-70
-10% -$32.3K 0.02% 573
2025
Q1
$335K Buy
+691
New +$322K 0.02% 501
2024
Q4
Sell
-1,052
Closed -$489K 766
2024
Q3
$489K Buy
+1,052
New +$505K 0.03% 476
2024
Q1
Sell
-947
Closed -$385K 732
2023
Q4
$385K Buy
947
+43
+5% +$15.9K 0.03% 477
2023
Q3
$314K Sell
904
-63
-7% -$22K 0.03% 497
2023
Q2
$340K Buy
+967
New +$326K 0.03% 474
2022
Q4
Sell
-722
Closed -$208K 797
2022
Q3
$208K Buy
+722
New +$208K 0.01% 738
2022
Q2
Sell
-989
Closed -$257K 860
2022
Q1
$257K Buy
+989
New +$235K 0.01% 725

Other funds holding VRTX

Western Wealth Management's VRTX Position: Q1 2026 in Review

Western Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 160% in Q1 2026, buying an estimated $468K and bringing the position to 1,631 shares worth $728K. The position accounts for 0.03% of the portfolio, ranked #541.

Western Wealth Management first reported a position in VRTX in Q1 2022 and has held it in 11 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Western Wealth Management held 1,631 shares of Vertex Pharmaceuticals worth $728K as of Q1 2026.
  • Western Wealth Management bought 1,003 Vertex Pharmaceuticals shares in Q1 2026, an estimated $468K.
  • Vertex Pharmaceuticals made up 0.03% of Western Wealth Management's portfolio in Q1 2026, its #541 holding.
  • Western Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Western Wealth Management's 13F filing for Q1 2026, filed 19 May 2026.